TPF
REGN icon

Tribridge Partners Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Tribridge Partners Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Hold
343
– – 0.11% 66
2025
Q4 		$265K Hold
343
– – 0.11% 61
2025
Q3 		$206K Buy
+343
New +$194K 0.09% 70

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tribridge Partners Financial's REGN Position: Q1 2026 in Review

Tribridge Partners Financial held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 343 shares worth $261K. The position accounts for 0.11% of the portfolio, ranked #66.

Tribridge Partners Financial first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $265K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Tribridge Partners Financial held 343 shares of Regeneron Pharmaceuticals worth $261K as of Q1 2026.
  • Tribridge Partners Financial left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.11% of Tribridge Partners Financial's portfolio in Q1 2026, its #66 holding.
  • Tribridge Partners Financial first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Tribridge Partners Financial's Regeneron Pharmaceuticals position peaked at $265K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Tribridge Partners Financial's 13F filing for Q1 2026, filed 15 Apr 2026.